Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Multi-agent chemotherapy successfully induces remission in most naïve, high-grade canine lymphoma patients; however, disease recurrence is common. MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) is an effective rescue protocol used to re-induce remission, but is associated with gastrointestinal toxicity and can be a less desirable option for patients that previously failed vincristine-containing protocols. Therefore, alternative members of the vinca alkaloid family, such as vinblastine, could be potentially advantageous as substitutes for vincristine to reduce gastrointestinal toxicity and chemoresistance. The objective of this study was to report the clinical outcomes and toxicity of 36 dogs with relapsed or refractory multicentric lymphoma treated with a modified MOPP protocol whereby vincristine was replaced with vinblastine (MVPP). The overall response rate to MVPP was 25% with a median progression free survival of 15 days and a median overall survival of 45 days. MVPP at the prescribed doses resulted in modest and transient clinical benefit, but was well tolerated with no treatment delays or hospitalizations secondary to side effects. Given the minimal toxicity, dose intensification could be considered to improve clinical responses.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/vco.12913 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A phase Ib/II trial combining brentuximab vedotin with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone (BrEPEM) for older patients with untreated classical Hodgkin lymphoma: A multicentre GELTAMO trial.
Br J Haematol
July 2025
Department of Haematology, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Barcelona, Spain.
Classical Hodgkin lymphoma (cHL) has high curability following initial standard treatments. A less favourable outcome is observed in patients aged ≥60 (poorer tolerability and efficacy). Low-intensity chemotherapies are currently employed for this group of patients, although there is still a need for improvement.
View Article and Find Full Text PDFFertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial.
Lancet Oncol
August 2025
Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Cologne, Germany; German Hodgkin Study Group (GHSG), Cologne, Germany.
Background: BrECADD (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone) has shown higher efficacy and better acute tolerability than eBEACOPP (escalated doses of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) in newly diagnosed, advanced-stage classic Hodgkin lymphoma. In this secondary analysis of the HD21 trial, we aimed to compare gonadal function recovery and fertility outcomes between these two regimens.
Methods: In the multicentre, parallel, open-label, phase 3 HD21 trial, conducted across 233 trial sites in nine countries, patients aged 18-60 years with newly diagnosed, advanced-stage classic Hodgkin lymphoma and an Eastern Cooperative Oncology Group performance status of 0-2 were randomly assigned (1:1) to receive 4-6 cycles of eBEACOPP or BrECADD, guided by interim response.
Real-World Outcomes of PET-Adapted Treatment for Classic Hodgkin's Lymphoma: A Study From a Single Tertiary Care Center.
Cureus
May 2025
Clinical Hematology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, PAK.
Background Classic Hodgkin's lymphoma (CHL) is frequently treated using a positron emission tomography (PET)-directed approach, as demonstrated in the Response-Adapted Therapy for Hodgkin Lymphoma (RATHL) trial. This study aimed to compare real-world patient outcomes with those reported in the RATHL trial for individuals with advanced-stage disease. Methods This retrospective study included 169 adult patients aged 18 years and older (range 20-66 years).
View Article and Find Full Text PDFComparative effectiveness of different chemotherapies given to Nodular Lymphocyte Predominant Hodgkin Lymphoma patients: A retrospective study from Lahore, Pakistan.
Cancer Treat Res Commun
May 2025
Department of Biological Sciences, The Superior University Lahore, Pakistan.
Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) is a rare type of Hodgkin lymphoma. This retrospective study aims to find most efficient chemotherapy that gives high rates of Progression Free Survival (PFS) and overall survival (OS). In this study confirmed patients of NLPHL identified from different hospitals from 2011 to 2023.
View Article and Find Full Text PDFCause-Specific Mortality in a Cohort of 1,435 Patients With Hodgkin Lymphoma Treated Between 1985 and 2014: A Nationwide Chilean Cohort Study.
JCO Glob Oncol
May 2025
CHIMOMO Department, University of Modena and Reggio Emilia, Modena, Italy.
Purpose: Hodgkin lymphoma (HL) is classified as the first malignancy to be cured by a combination of chemotherapy and radiotherapy. However, the life expectancy of HL survivors is hampered by the occurrence of late adverse events, including second malignant neoplasms (SMNs) and cardiovascular diseases (CVDs).
Patients And Methods: We investigated the causes of death in a cohort of 1,435 patients over age 15 years treated at 18 different public cancer centers in Chile.